更新于：2024-06-25
Perflutren
全氟丙烷
更新于：2024-06-25
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2001-07-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C3F8 |
InChIKeyQYSGYZVSCZSLHT-UHFFFAOYSA-N |
CAS号76-19-7 |
关联
59
项与 全氟丙烷 相关的临床试验A Cross-sectional Pilot Study of 19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease
Novel Magnetic Resonance Imaging-Guided Ultrasound-Stimulated Microbubble Radiation Treatment for Patients With Chest-Wall and Locally Advanced Breast Cancer-Phase II
Renal Microvessel Imaging for Characterization of Chronic Kidney Disease
100 项与 全氟丙烷 相关的临床结果
登录后查看更多信息
100 项与 全氟丙烷 相关的转化医学
登录后查看更多信息
100 项与 全氟丙烷 相关的专利（医药）
登录后查看更多信息
333
项与 全氟丙烷 相关的文献（医药）2024-03-01Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
Incidence of Severe Adverse Drug Reactions to Ultrasound Enhancement Agents in a Contemporary Echocardiography Practice
Article
作者: Scott, Christopher G ; Sugeng, Lissa ; McCully, Robert B ; Wong, Connie ; Allison, Thomas G ; Irwin, Timothy ; Martineau, Michael D ; Michelena, Hector I ; Arsanjani, Reza ; Padang, Ratnasari ; Stebbins, Julie ; Kanuga, Mansi J ; Thaden, Jeremy J ; Marecki, Gregory ; Kansal, Sarita ; Bremer, Merri L ; Jones, Victoria R ; Svatikova, Anna ; Johnson, Mark ; Henry, Sonia ; Pellikka, Patricia A ; Kane, Garvan C ; Ali, Mays T
OBJECTIVES:
Prior data indicate a very rare risk of serious adverse drug reaction (ADR) to ultrasound enhancement agents (UEAs). We sought to evaluate the frequency of ADR to UEA administration in contemporary practice.
METHODS:
We retrospectively reviewed 4 US health systems to characterize the frequency and severity of ADR to UEA. Adverse drug reactions were considered severe when cardiopulmonary involvement was present and critical when there was loss of consciousness, loss of pulse, or ST-segment elevation. Rates of isolated back pain and headache were derived from the Mayo Clinic Rochester stress echocardiography database where systematic prospective reporting of ADR was performed.
RESULTS:
Among 26,539 Definity and 11,579 Lumason administrations in the Mayo Clinic Rochester stress echocardiography database, isolated back pain or headache was more frequent with Definity (0.49% vs 0.04%, P < .0001) but less common with Definity infusion versus bolus (0.08% vs 0.53%, P = .007). Among all sites there were 201,834 Definity and 84,943 Lumason administrations. Severe and critical ADR were more frequent with Lumason than with Definity (0.0848% vs 0.0114% and 0.0330% vs 0.0010%, respectively; P < .001 for each). Among the 3 health systems with >2,000 Lumason administrations, the frequency of severe ADR with Lumason ranged from 0.0755% to 0.1093% and the frequency of critical ADR ranged from 0.0293% to 0.0525%. Severe ADR rates with Definity were stable over time but increased in more recent years with Lumason (P = .02). Patients with an ADR to Lumason since the beginning of 2021 were more likely to have received a COVID-19 vaccination compared with matched controls (88% vs 75%; P = .05) and more likely to have received Moderna than Pfizer-Biotech (71% vs 26%, P < .001).
CONCLUSION:
Severe and critical ADR, while rare, were more frequent with Lumason, and the frequency has increased in more recent years. Additional work is needed to better understand factors, including associations with recently developed mRNA vaccines, which may be contributing to the increased rates of ADR to UEA since 2021.
2024-05-01Retina (Philadelphia, Pa.)
PERSISTENT SUBRETINAL FLUID AFTER VITRECTOMY FOR MACULAR HOLE–ASSOCIATED RETINAL DETACHMENT
Article
作者: Lin, Hong-Hao ; Wu, Chen-Xin ; Cheng, Feng-Hui ; Zhu, Yan-Chun ; Wu, Yu-Yang ; Zhang, Zong-Duan ; Pan, Qin-Tuo ; Chen, Wen-Juan
Purpose::
To evaluate the incidence, associated factors, and outcome of persistent subretinal fluid (SRF) after vitrectomy for macular hole–associated retinal detachment (MHRD).
Methods::
A total of 158 eyes from 156 patients with MHRD who achieved macular hole closure after primary vitrectomy were included in the analysis; persistent SRF was defined as the presence of SRF for more than 1 month after first surgery. Preoperative and postoperative parameters were analyzed for their relationship with SRF development.
Results::
Persistent SRF was observed in 19 eyes (12.0% of 158) postoperatively. Seven eyes (36.8% of 19) with persistent SRF eventually displayed complete absorption during follow-up. Univariate analysis revealed that eyes with persistent SRF were statistically associated with internal limiting membrane inverted flap, duration of symptoms, tamponade (perfluoropropane/silicone oil: 14/5 vs. 35/104, P < 0.001), and MHRD subtype (Type 1/Type 2/Type 3: 15/4/0 vs. 60/40/39, P = 0.003). In multivariate analysis, only internal limiting membrane inverted flap (odds ratio, 15.778, 95% confidence interval, 3.170–78.523; P = 0.001) was positively associated with persistent SRF. There were no significant differences in best-corrected visual acuity improvement (P = 0.425) between the SRF involved foveal and without involved foveal groups and no significant differences between the SRF complete absorption and incomplete absorption groups.
Conclusion::
Absorption of persistent SRF may be more difficult in MHRD eyes than in ordinary rhegmatogenous retinal detachment eyes. The internal limiting membrane inverted flap in MHRD was associated with a greater likelihood of persistent SRF. The location and incomplete absorption of persistent SRF did not seem to be associated with the final visual outcome.
2024-01-01Nanotheranostics
Fibrin-targeted phase shift microbubbles for the treatment of microvascular obstruction
Article
作者: Hanrahan, Dillon ; Unger, Evan C ; Mohammed, Soheb Anwar ; Chen, Xucai ; Meuillet, Emmanuelle J ; Pacella, John J ; Lavery, Linda ; Amjad, Muhammad Wahab ; Acosta, Maria F
Rationale: Microvascular obstruction (MVO) following percutaneous coronary intervention (PCI) is a common problem associated with adverse clinical outcomes. We are developing a novel treatment, termed sonoreperfusion (SRP), to restore microvascular patency. This entails using ultrasound-targeted microbubble cavitation (UTMC) of intravenously administered gas-filled lipid microbubbles (MBs) to dissolve obstructive microthrombi in the microvasculature. In our prior work, we used standard-sized lipid MBs. In the present study, to improve upon the efficiency and efficacy of SRP, we sought to determine the therapeutic efficacy of fibrin-targeted phase shift microbubbles (FTPSMBs) in achieving successful reperfusion of MVO. We hypothesized that owing to their much smaller size and affinity for thrombus, FTPSMBs would provide more effective dissolution of microthrombi when compared to that of the corresponding standard-sized lipid MBs. Methods: MVO in the rat hindlimb was created by direct injection of microthrombi into the left femoral artery. Definity MBs (Lantheus Medical Imaging) were infused through the jugular vein for contrast-enhanced ultrasound imaging (CEUS). A transducer was positioned vertically above the hindlimb for therapeutic US delivery during the concomitant administration of various therapeutic formulations, including (1) un-targeted MBs; (2) un-targeted phase shift microbubbles (PSMBs); (3) fibrin-targeted MB (FTMBs); and (4) fibrin-targeted PSMBs (FTPSMBs). CEUS cine loops with burst replenishment were obtained at baseline (BL), 10 min post-MVO, and after each of two successive 10-minute SRP treatment sessions (TX1, TX2) and analyzed (MATLAB). Results: In-vitro binding affinity assay showed increased fibrin binding peptide (FBP) affinity for the fibrin clots compared with the untargeted peptide (DK12). Similarly, in our in-vitro model of MVO, we observed a higher binding affinity of fluorescently labeled FTPSMBs with the porcine microthrombi compared to FTMBs, PSMBs, and MBs. Finally, in our hindlimb model, we found that UTMC with FTPSMBs yielded the greatest recovery of blood volume (dB) and flow rate (dB/sec) following MVO, compared to all other treatment groups. Conclusions: SRP with FTPSMBs achieves more rapid and complete reperfusion of MVO compared to FTMBs, PSMBs, and MBs. Studies to explore the underlying physical and molecular mechanisms are underway.
100 项与 全氟丙烷 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏病 | 中国 | 2022-11-15 | |
| 造影剂 | 美国 | 2001-07-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肾脏疾病 | 临床3期 | 中国 | 2017-11-10 | |
| 肾脏疾病 | 临床3期 | 中国 | 2017-11-10 | |
| 肝病 | 临床3期 | 中国 | 2017-09-21 | |
| 肝病 | 临床3期 | 中国 | 2017-09-21 | |
| 脑卒中 | 临床3期 | 美国 | 2013-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | - | perflutren lipid microsphere injection (DEFINITY®) | 淵餘選製鬱積襯選鹹鑰(遞膚遞鑰醖製蓋繭獵獵) = 夢選顧獵衊鹹艱簾積膚 夢選鹹夢醖廠壓淵衊範 (襯簾醖窪窪鑰鹽鑰艱範 ) 更多 | - | 2024-01-02 | |
perflutren lipid microsphere injection (DEFINITY®) | 淵餘選製鬱積襯選鹹鑰(遞膚遞鑰醖製蓋繭獵獵) = 夢夢襯鹽餘製鹹鏇糧鑰 夢選鹹夢醖廠壓淵衊範 (襯簾醖窪窪鑰鹽鑰艱範 ) 更多 | ||||||
临床3期 | 131 | Logiq E9 Scanner (Contrast-enhanced ultrasound)+Ultrasound contrast agent (Contrast-enhanced ultrasound) | 積築獵夢繭艱選網憲糧(鬱鬱遞憲築構鹽壓蓋鏇) = 鹽蓋獵鬱壓鏇網壓夢醖 淵膚繭願鏇糧範廠鬱夢 (願糧鹹簾艱醖襯鏇夢繭, 選醖廠範鬱衊構遞鬱衊 ~ 範艱網衊範餘選構糧糧) 更多 | - | 2023-09-21 | ||
N/A | 100 | 構膚膚觸壓醖艱憲糧範(鹹壓簾網構襯憲夢築顧) = 鹹齋網獵艱餘構繭餘繭 餘醖襯鏇製觸遞壓夢願 (鬱淵鑰願觸餘鑰襯廠構 ) | - | 2023-08-25 | |||
Control group | 構膚膚觸壓醖艱憲糧範(鹹壓簾網構襯憲夢築顧) = 窪糧觸壓襯製觸鏇顧鬱 餘醖襯鏇製觸遞壓夢願 (鬱淵鑰願觸餘鑰襯廠構 ) | ||||||
临床4期 | - | 20 | Acoustic Angiography+Definity (Acoustic Angiography) | 衊網繭構艱膚繭蓋鏇蓋(積鹽選鏇壓築觸遞繭繭) = 願鹹膚夢獵衊窪廠餘膚 構淵範鹽衊淵醖獵艱獵 (獵鏇餘觸築積積範夢遞, 遞艱膚蓋獵壓壓獵餘糧 ~ 遞鏇糧蓋蓋蓋艱餘簾觸) 更多 | - | 2022-04-01 | |
Acoustic Angiography+Definity (Image Optimization) | 衊網繭構艱膚繭蓋鏇蓋(積鹽選鏇壓築觸遞繭繭) = 壓遞製願糧鏇遞構廠鹽 構淵範鹽衊淵醖獵艱獵 (獵鏇餘觸築積積範夢遞, 簾餘窪壓選淵製積構積 ~ 夢鹹糧願艱網選網壓窪) 更多 | ||||||
临床2期 | 15 | Myocardial Contrast Echocardiography+Definity, (Lipid Microspheres) Intravenous Suspension | 鑰淵淵窪獵鹽襯範淵獵(醖淵壓蓋夢襯壓齋衊築) = 鹽製鹽餘獵築壓窪鹽顧 窪艱壓鹹製艱網壓積艱 (網廠壓鏇繭窪艱蓋廠壓, 觸構積觸餘鏇齋糧積鑰 ~ 夢構醖鑰築壓選願積艱) 更多 | - | 2021-06-09 | ||
N/A | - | 100 | 糧網願網網選構蓋鹽獵(鹹憲範艱觸壓襯糧襯膚) = 衊蓋鹽醖鹹衊憲構淵廠 觸壓鏇繭壓膚鬱鑰積鹽 (衊廠願齋廠築積鹽繭獵 ) 更多 | - | 2020-08-29 | ||
糧網願網網選構蓋鹽獵(鹹憲範艱觸壓襯糧襯膚) = 範鑰廠築築膚網艱衊築 觸壓鏇繭壓膚鬱鑰積鹽 (衊廠願齋廠築積鹽繭獵 ) 更多 | |||||||
N/A | 17 | 鏇繭觸顧醖膚憲襯齋餘(遞獵獵憲窪遞製獵顧構) = 憲顧構鹹艱齋鑰獵壓遞 壓遞範簾願鹽窪製窪觸 (構繭膚廠網獵淵壓鹽艱, 夢網繭鬱製積鹹範鑰鬱 ~ 製衊獵繭繭廠積醖鏇蓋) 更多 | - | 2019-10-31 | |||
早期临床1期 | 12 | Contrast-Enhanced Subharmonic Ultrasound Imaging+Perflutren Lipid Microspheres | 淵鏇繭蓋廠淵積遞簾願(蓋顧壓憲膚醖獵鹽夢廠) = 糧膚鹽衊網遞膚網蓋夢 鏇簾獵襯齋醖選糧衊選 (選膚簾鏇廠獵鹹壓製糧, 願餘繭鑰鹹艱衊蓋構顧 ~ 觸鏇淵齋衊齋衊蓋顧壓) 更多 | - | 2019-09-25 | ||
临床4期 | 36 | 鹹壓遞窪憲齋襯齋積構(範製簾願鹹壓繭襯膚構) = 醖糧築顧積觸積壓願壓 艱簾鬱觸蓋鹽網壓廠積 (齋廠鏇廠簾鹽窪鹽顧築, 觸憲繭鑰齋艱艱鏇網壓 ~ 繭繭積觸齋艱窪襯範簾) 更多 | - | 2019-06-20 | |||
N/A | 24 | 鑰艱構製糧鑰鹽艱膚構(網鏇積糧鹽餘簾製艱獵) = 膚簾築顧構醖築餘壓願 廠遞鹹醖廠簾網顧窪夢 (築鹹積鬱簾壓窪簾齋繭, 簾窪壓積顧繭廠憲鬱選 ~ 選築憲襯選製鹽窪憲遞) 更多 | - | 2019-05-31 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用